Qualigen Therapeutics, Inc. announced that it has entered into a Securities Purchase Agreement with returning investor, Alpha Capital Anstalt to issue an 8% Convertible Debenture in the principal amount of $550,000 and to issue a 5-year common stock purchase warrant to purchase 900,016 shares of common stock of the company at an exercise price of $0.26 per share for the gross proceeds of $550,000 on February 26, 2024. The Debenture would have a maturity date of December 31, 2024 and would be convertible, at any time, and from time to time, at investor?s option, into shares of common stock of the Company, at $0.6111 per share, subject to adjustment as described in the Debenture. The Debenture would accrue interest on its outstanding principal balance at the rate of 8% per annum, which would be payable at maturity.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.27 USD | -1.17% | -11.48% | -50.91% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-50.91% | 1.7M | |
+43.36% | 54.63B | |
-5.31% | 39.92B | |
+14.75% | 26.86B | |
-12.56% | 26.22B | |
-22.45% | 18.78B | |
+25.12% | 12.21B | |
+0.04% | 12.16B | |
+26.04% | 11.94B | |
-11.83% | 10.74B |
- Stock Market
- Equities
- QLGN Stock
- News Qualigen Therapeutics, Inc.
- Qualigen Therapeutics, Inc. announced that it expects to receive $0.55 million in funding from Alpha Capital Anstalt